In recent years, with the rapid development of China's economy and the continuous improvement of the living standards of domestic residents, the domestic pharmaceutical market's demand for imported pharmaceutical products is also expanding, and the requirements are also getting higher and higher, which to some extent prompted China's pharmaceutical regulatory authorities to strengthen the supervision of imported pharmaceutical products.

1. As China's drug-related laws and regulations are updated rapidly, it is hard for overseas enterprises to pay attention to the update of drug-related laws and regulations in time and to organize production in accordance with the latest drug-related laws and regulations in China;

2.The registration information submitted to CFDA is usually not consistent with its overseas production status and the latest product information, and may not update the relevant content of the registration information according to the actual situation of the production site and the latest product standards;

1. the specialty and style of inspection;

2. Specific procedures of inspection;

3. Legal basis for inspection;

4. Scope and intensity of inspection;

5. Focus of inspection;

6. Judgment of inspection results

As a subsidiary of Tigermed, we have a strong background and work with Tigermed Group and other sister companies to provide a one-stop service platform for domestic and international clients from R&D, registration, and transformation to production.

Over the last two decades, Canny has formed a mature and standardized service system in terms of consultant team, service standards, service protocols, project management and confidentiality system, and has passed ISO 9001 quality management system certification for many years, providing professional services to more than 1370+ Chinese and foreign clients in total.